Dimension Bio

Name

Dimension Bio

Legal name

Dimension Bio

Website

https://dimension.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Dimension Bio is a clinical-stage biotechnology company developing regenerative therapeutics using its BioNidum 3D-printed cell delivery platform. The company targets liver failure as its lead indication and serves biotech partners developing cell therapies that require advanced biomaterial delivery systems.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

Keywords

• Regenerative therapeutics
• Biomaterial scaffolds
• Cell delivery systems
• 3D bioprinting
• Tissue engineering

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Regenerative Therapeutics: Dimension Bio is a clinical-stage biotechnology company developing regenerative therapeutic products. As a pre-revenue company, they are focused on developing implantable and injectable biosynthetic products for tissue regeneration. The company has an FDA-cleared biomaterial (CMFlex) and is advancing toward clinical trials for liver failure treatment.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Dimension Bio designs, develops, and manufactures regenerative therapeutics built on its BioNidum™ platform, a bioinspired cell delivery system that fuses materials science, 3D printing, and digital manufacturing to transform cells into implantable, tissue-like therapies. The company is advancing an implantable cell therapy for liver failure as its lead program and commercialized CMFlex™, the first FDA-cleared 3D-printed regenerative bone graft for oral and maxillofacial indications, powered by Hyperelastic Bone® technology.

Product overview

Dimension Bio is a biotechnology company pioneering regenerative therapeutics with BioNidum™ as its core bioinspired platform that enables the transformation of cells into implantable, tissue-like therapies. The platform leverages materials science, 3D printing, and digital manufacturing to create regenerative microenvironments. Built on this platform, the company is developing an implantable cell therapy for liver failure as its lead program. Previously, under the Dimension Inx name, the company commercialized CMFlex™ (powered by Hyperelastic Bone® technology), the first FDA-cleared 3D-printed regenerative bone graft product for oral and maxillofacial applications. The product portfolio spans both internal therapeutic development and strategic partner programs across tissue regeneration applications.

Differentiator

Problem solved

Functional benefit

Brands

• BioNidum: The company's bioinspired cell delivery system platform that fuses materials science, 3D printing, and digital manufacturing to transform cells into implantable, tissue-like therapies for regenerative medicine.
• CMFlex
• Hyperelastic Bone

Products and services

• BioNidum™ Bioinspired cell delivery platform that fuses materials science, 3D printing, and digital manufacturing to transform cells into implantable, tissue-like therapies for regenerative medicine applications. Supports both implantable and injectable products across tissue regeneration and cell delivery use cases.
• CMFlex™ Flexible, ready-to-use 3D-printed synthetic bone graft substitute and the first 3D-printed regenerative bone product cleared by the FDA for oral and maxillofacial indications. For oral and maxillofacial surgeons and dental practices.
• Hyperelastic Bone® Unique synthetic bone graft material offering a more effective and user-friendly regenerative solution for clinical applications; serves as the technology foundation underlying CMFlex.

Quantifiable outcome

• 70% survival improvement in preclinical liver failure models compared to controls
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• ReGen Valley Tech HubcoreStrategic or Co-development Partner · 27 August 2025Dimension Bio was selected to receive commercialization resource awards from the ReGen Valley Tech Hub. Support spans strategic regulatory services, manufacturing strategy, and reimbursement strategy to accelerate the path of its implantable cell therapy for liver failure from development to market. The Tech Hub is coordinated by ARMI and backed by approximately $44 million in EDA implementation funding.
• ARMI (Advanced Regenerative Manufacturing Institute)coreStrategic or Co-development Partner · 27 August 2025ARMI coordinates the ReGen Valley Tech Hub, a consortium of more than 40 organizations. The goal is to secure domestic leadership in biofabrication by scaling commercialization resources, expanding advanced manufacturing infrastructure, and nurturing a skilled workforce in New Hampshire's Manchester-Nashua region.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Humacyte: Humacyte is a clinical-stage regenerative medicine company developing bioengineered human tissues (e.g., Symvess for vascular trauma). Comparable as a clinical-stage platform that manufactures implantable tissue therapeutics using proprietary scaffold and cell processes, with similar regulatory pathway and indication breadth.
• Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting platforms for creating physiologically relevant tissue therapeutics, including pancreatic islet cell therapies for Type 1 diabetes. Highly comparable to Dimension Bio's BioNidum platform in combining 3D printing, biomaterials, and cell therapy, with overlapping indications in metabolic disease.
• Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic and research applications. Direct peer on the bioprinting technology axis, although Organovo's focus has historically skewed toward disease modeling and liver tissue patches, both of which overlap with Dimension Bio's therapeutic ambition.

Broad incumbents

• MiMedx Group: MiMedx commercializes placental tissue allografts (e.g., EpiFix, AmnioFix) for wound care, orthopedics, and surgical recovery. Comparable as a publicly traded regenerative medicine company with established commercial products in adjacent tissue repair indications (sports medicine, orthopedics, wound healing).
• BICO (CELLINK): BICO owns CELLINK and a portfolio of bioprinting, biosciences, and diagnostics companies supplying bioprinters, bioinks, and lab automation. It is a broader incumbent in the 3D bioprinting ecosystem that supplies tools used by companies like Dimension Bio and competes at the platform level for tissue-engineering customers.
• United Therapeutics: United Therapeutics is a diversified biotech with significant programs in organ manufacturing, xenotransplantation, and regenerative medicine (including lung, kidney, and heart efforts). Broad incumbent comparable to Dimension Bio on the ambition to manufacture replacement organ tissue, with greater resources and broader indication scope.
• Vericel Corporation: Vericel develops autologous cell therapies including MACI (cartilage repair) and Epicel (burns), and is also a board-relevant comparison given Heidi Hagen's Vericel directorship. Comparable as a commercial-stage cell therapy company in regenerative medicine with established orthopedic and wound-healing indications adjacent to Dimension Bio's pipeline.

Emerging players

• LyGenesis: LyGenesis is developing an in-body organ regeneration technique that grows ectopic functional liver tissue in lymph nodes of patients with liver failure. Direct emerging competitor in the liver failure indication using a different regenerative approach, targeting the same unmet need that Dimension Bio's BioNidum hepatocyte program addresses.
• Promethera Biosciences: Promethera (now operating as a liver-focused cell therapy unit) develops HepaStem and other allogeneic cell therapies for liver disease, including acute-on-chronic liver failure. Emerging competitor with direct overlap on the cell-based liver failure indication, providing both partnership and competitive context for Dimension Bio's lead program.

Others

• ARMI / BioFabUSA: ARMI's BioFabUSA consortium and the ReGen Valley Tech Hub (which awarded Dimension Bio commercialization resources) is an enabling ecosystem of more than 40 organizations developing standardized manufacturing processes for regenerative medicine. Not a direct competitor, but a strategic infrastructure partner comparable in scope to Dimension Bio's manufacturing ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimension Bio